ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - olanzapine 15 mg - film coated tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine teva® is indicated for the management of the manifestations of psychotic disorders. olanzapine teva® is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.prevention of recurrence in bipolar disorder: in patients whose manic episode has responded to olanzapine treatment olanzapine teva® is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder. the combination of olanzapine teva® with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - olanzapine 5 mg - tablets orodispersible - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine odt teva is indicated for the management of the manifestations of psychotic disorders. olanzapine odt teva is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment olanzapine odt teva is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine odt teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

salomon,levin & elstein ltd - olanzapine 10 mg - tablets orodispersible - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine odt teva is indicated for the management of the manifestations of psychotic disorders. olanzapine odt teva is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder : in patients whose manic episode has responded to olanzapine treatment olanzapine odt teva is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine odt teva with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - olanzapine 5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - olanzapine 7.5 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - olanzapine 10 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder : the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - olanzapine 15 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - olanzapine 20 mg - tablets - olanzapine - acute and maintenance treatment of schizophrenia. olanzapine is indicated for the management of the manifestations of psychotic disorders. olanzapine is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder. prevention of recurrence in bipolar disorder: in patients whose manic episodes has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. combination therapy in bipolar i disorder: the combination of olanzapine with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr

ישראל - עברית - Ministry of Health

eli lilly israel ltd - olanzapine 300 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr